Olema enters clinical trial agreement with Pfizer for palazestrant + atirmociclib phase 1b/2

Olema Pharmaceuticals, Inc.

Phase 1b/2 study to evaluate safety and combinability of palazestrant plus Pfizer’s investigational CDK4 inhibitor atirmociclib in ER+/HER2- metastatic breast cancer.
Study planned for approximately 35 patients with initiation anticipated in H2 2025.
Results to inform potential Phase 3 pivotal trial in frontline metastatic setting.
Olema retains full global commercial and marketing rights to palazestrant; Pfizer supplies atirmociclib.
This is Olema’s second clinical trial agreement with Pfizer; prior agreement from Nov 2020 for palazestrant + palbociclib.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.